Important update: The BC Centre on Substance Use is developing new guidance in the context of COVID-19. Here's the latest information for OAT prescribers and pharmacists:
Please refer to our Bulletins section on this page for the latest information.
* * *
Opioid use disorder is one of the most challenging forms of addiction facing the health care system in British Columbia and a major driver of illicit drug overdose deaths in the province.
In the context of the current public health emergency, the BC Centre on Substance Use has developed provincial evidence-based guidelines articulating the full range of therapeutic options for the optimal treatment of adults and youth with varying presentations of opioid use disorder.
These guidelines are intended for use for all BC physicians, nursing and allied health professionals, and other care providers involved in the treatment of individuals with opioid use disorder. While this guideline supports the diversity of possible treatments available for individuals with opioid use disorder, it strongly recommends against a strategy involving withdrawal management alone, since this approach has been associated with elevated risk of HIV and hepatitis C transmission, elevated rates of overdose deaths in comparison to providing no treatment, and nearly universal relapse when implemented without plans for transition to long-term evidence-based addiction treatment (e.g., opioid agonist treatment). However, this guideline also acknowledges the importance of strengthening the residential treatment system with a view to aiding individuals seeking long-term cessation of opioid use who do not wish to pursue pharmacological treatment, but may still wish to use other various pharmacotherapies for symptom management during withdrawal.
Opioid Use Disorder Guidelines:
- Sublocade (Extended-Release Buprenorphine) Information - May 29, 2020
- COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists - March 31, 2020
- Opioid Agonist Treatment Alert - SROM - March 9, 2020
- Methadone Formulations Options Bulletin - January 20, 2020
- Compounded Methadone Bulletin - January 20, 2020
- Metadol Update - May 28, 2019
- Withdrawal Management
- Consent Form for Withdrawal Management
- Safer Tablet Injection: A Resource for Clinicians Providing Care to Patients Who May Inject Oral Formulations
- Methadone Chart: Formulation Information, Differences, and Preparation Details
- Buprenorphine-Naloxone Treatment Agreement and Consent Form
- Clinical Opiate Withdrawal Scale
- DSM-5 Criteria for opioid Use Disorder
- Methadone Treatment Agreement and Consent Form
- Patient Agreement for Take Home Dosing
- Patient Assessment for Opioid Agonist Treatment
- Subjective Opiate Withdrawal Scale (SOWS)
- LOUD in the ED: Emergency Department Buprenorphine/naloxone Induction: Decision Support Tool
As of June 5, 2017, the BCCSU is responsible for the educational and clinical care guidance activities for all health care professionals who are prescribing medications to treat opioid addiction (i.e., methadone, buprenorphine/naloxone, slow-release oral morphine, injectable opioid agonist treatment). If you are seeking education and training for these treatment options, please visit our Provincial Opioid Addiction Treatment Support Program (POATSP) page. Additional training and educational resources for managing opioid use disorder are available as noted below.
Education & Training Resources: